Norditropin Injection is a synthetic form of human growth hormone used to treat growth-related disorders. It is prescribed for children with growth hormone deficiency, Turner syndrome, or chronic kidney disease, and for adults with insufficient natural growth hormone production. The injection helps improve growth rates, increase muscle mass, and support overall metabolic health. Norditropin is part of a structured treatment plan that includes regular medical monitoring and lifestyle adjustments.

Norditropin mimics the body’s natural growth hormone, binding to receptors in tissues to stimulate growth and repair. It enhances protein synthesis, promotes fat breakdown, and increases the production of insulin-like growth factor-1 (IGF-1), which plays a critical role in bone growth and muscle development. The hormone also supports energy metabolism, helps regulate blood sugar, and improves body composition by increasing lean muscle and reducing fat stores.

This medication should not be used by individuals with active cancer, untreated thyroid problems, or acute illnesses such as critical respiratory conditions or major surgery. It is contraindicated in children with closed growth plates and should be avoided in those with known hypersensitivity to growth hormone products. Patients with diabetes, cardiovascular diseases, or a history of hormone-sensitive tumors require close supervision during treatment. Regular follow-up is essential to assess growth progress and detect potential side effects early.

Some common side effects include injection site irritation, headaches, muscle pain, and joint stiffness. Others may experience water retention, fatigue, or mild dizziness. Rare but serious effects include changes in glucose levels, thyroid hormone imbalance, or increased intracranial pressure, leading to headaches and visual disturbances. Long-term use may also affect bone growth or lead to hormonal irregularities, so ongoing medical supervision is recommended.

Norditropin is not recommended for use during pregnancy unless the potential benefits outweigh the risks, as the effects on fetal development are not fully understood. Women who are pregnant or planning to become pregnant should consult their healthcare provider before using this medication. It is also unclear whether the hormone passes into breast milk, so breastfeeding mothers should discuss alternative treatment options and closely monitor the infant’s health if its use is deemed necessary.

Once a Norditropin pen is in use, the pen should be stored in the refrigerator (2 to 8 °C; 36 to 46 °F), and used within 4 weeks. Alternatively, the Norditropin pens may be stored in the pen at room temperatures, no higher than 25°C (77°F), for up to 3 weeks. NovoFine needles are recommended for administration. Wipe the stopper on the needle thread with rubbing alcohol to prevent contamination.15

Do not use a reconstituted solution if cloudy or contains particulate matter. Before use, store under refrigeration at 2 to 8°C (36 to 46°F).

Keep all medicines out of the reach of children. Throw away any unused medicine after the beyond-use date. Do not flush unused medications or pour them down a sink or drain.

1. Omnitrope (somatropin) package insert. Princeton, NJ: Sandoz, Inc.; 2016 Dec.
2. Genotropin (somatropin) package insert. New York, NY: Pharmacia & Upjohn Company; 2016 Dec.
3. Food and Drug Administration (US FDA) Drug Safety Communication. Safety review update of Recombinant Human Growth Hormone (somatropin) and possible increased risk of death. Retrieved August 4, 2011. Available on the WorldWide Web at: http://www.f– LinkOpens in New Tab
4. Albertsson-Wikland K, Martensson A, Savendalh L, et al. Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab. 2016; 101: 2149-2159.
5. Humatrope (somatropin) package insert. Indianapolis, IN: Eli Lilly and Company; 2016 Dec.
6. Serostim (somatropin) package insert. Rockland, MA: EMD Serono, Inc.; 2017 May.
7. Nutropin (somatropin) package insert. San Francisco, CA: Genentech; 2016 Dec.
8. Accretropin (somatropin) package insert. Winnipeg, Canada: Cangene Corporation; 2016 Dec.
9. Nutropin AQ (somatropin) package insert. San Francisco, CA: Genentech; 2016 Dec.
10. Saizen (somatropin) package insert. Rockland, MA: EMD Serono Inc; 2017 May.
11. Norditropin (somatropin) package insert. Plainsboro, NJ: Novo Nordisk; 2016 Dec.
12. Zomacton (somatropin) package insert. Parsippany, NJ: Ferring Pharmaceuticals, Inc; 2016 Dec.
13. Zorbtive (somatropin) injection package insert. Rockland, MA: EMD Serono, Inc.; 2017 May.
14. The American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227-46.
15. Zomig (zolmitriptan) nasal spray package insert. Hayward, CA: Impax Specialty Pharma; 2015 Jun.